CONTEXT: The study investigated the regulation of matrix metalloproteinases (MMP)-9 in obesity-associated insulin resistance in humans. OBJECTIVES: The objectives of the investigation were to study MMP-9 regulation by insulin resistance and pioglitazone treatment in impaired glucose tolerant subjects using adipose tissue biopsies and study the mechanism of MMP-9 regulation by pioglitazone in adipocyte cultures. RESEARCH DESIGN:86 nondiabetic, weight-stable subjects between 21 and 66 yr of age were recruited in a university hospital research center setting. All subjects underwent a sc adipose tissue incisional biopsy from the lower abdominal wall and insulin sensitivity testing using a frequently sampled iv glucose tolerance test. Impaired glucose-tolerant subjects were randomized to receive metformin or pioglitazone for 10 wk. To study the mechanism of MMP-9 regulation in adipocytes, cells were treated with pioglitazone or protein kinase C alpha antisense oligomers, and MMP-9 levels were examined. RESULTS: There was a positive correlation between MMP-9 and body mass index (r = 0.40, P < 0.01) and negative correlation between MMP-9 and insulin sensitivity (r = -0.46, P < 0.001). The improvement in insulin sensitivity from pioglitazone resulted in a 52 +/- 0.2% reduction in MMP-9 mRNA. Fractionation of adipose tissue indicated that MMP-9 was mostly in the stromal vascular fraction. Pioglitazone also decreased MMP-9 in 3T3-F442A adipocytes and THP1 macrophages. Coculture of adipocytes with macrophages augmented MMP-9 expression in adipocytes and pioglitazone decreased MMP-9 in both adipocytes and macrophages. CONCLUSION: These data indicate that MMP-9 is elevated in insulin resistance and is reduced by pioglitazone.
RCT Entities:
CONTEXT: The study investigated the regulation of matrix metalloproteinases (MMP)-9 in obesity-associated insulin resistance in humans. OBJECTIVES: The objectives of the investigation were to study MMP-9 regulation by insulin resistance and pioglitazone treatment in impaired glucose tolerant subjects using adipose tissue biopsies and study the mechanism of MMP-9 regulation by pioglitazone in adipocyte cultures. RESEARCH DESIGN: 86 nondiabetic, weight-stable subjects between 21 and 66 yr of age were recruited in a university hospital research center setting. All subjects underwent a sc adipose tissue incisional biopsy from the lower abdominal wall and insulin sensitivity testing using a frequently sampled iv glucose tolerance test. Impaired glucose-tolerant subjects were randomized to receive metformin or pioglitazone for 10 wk. To study the mechanism of MMP-9 regulation in adipocytes, cells were treated with pioglitazone or protein kinase C alpha antisense oligomers, and MMP-9 levels were examined. RESULTS: There was a positive correlation between MMP-9 and body mass index (r = 0.40, P < 0.01) and negative correlation between MMP-9 and insulin sensitivity (r = -0.46, P < 0.001). The improvement in insulin sensitivity from pioglitazone resulted in a 52 +/- 0.2% reduction in MMP-9 mRNA. Fractionation of adipose tissue indicated that MMP-9 was mostly in the stromal vascular fraction. Pioglitazone also decreased MMP-9 in 3T3-F442A adipocytes and THP1 macrophages. Coculture of adipocytes with macrophages augmented MMP-9 expression in adipocytes and pioglitazone decreased MMP-9 in both adipocytes and macrophages. CONCLUSION: These data indicate that MMP-9 is elevated in insulin resistance and is reduced by pioglitazone.
Authors: Theodore P Ciaraldi; Alice P S Kong; Neelima V Chu; Dennis D Kim; Sunita Baxi; Mattias Loviscach; Ray Plodkowski; Richard Reitz; Michael Caulfield; Sunder Mudaliar; Robert R Henry Journal: Diabetes Date: 2002-01 Impact factor: 9.461
Authors: Gouri Ranganathan; Wei Song; Nicholas Dean; Brett Monia; Steven W Barger; Philip A Kern Journal: J Biol Chem Date: 2002-07-30 Impact factor: 5.157
Authors: Ray C Boston; Darko Stefanovski; Peter J Moate; Anne E Sumner; Richard M Watanabe; Richard N Bergman Journal: Diabetes Technol Ther Date: 2003 Impact factor: 6.118
Authors: Magdalena Pasarica; Olga R Sereda; Leanne M Redman; Diana C Albarado; David T Hymel; Laura E Roan; Jennifer C Rood; David H Burk; Steven R Smith Journal: Diabetes Date: 2008-12-15 Impact factor: 9.461
Authors: Yoshinori Seki; Masako Suzuki; Xingyi Guo; Alan Scott Glenn; Patricia M Vuguin; Ariana Fiallo; Quan Du; Yi-An Ko; Yiting Yu; Katalin Susztak; Deyou Zheng; John M Greally; Ellen B Katz; Maureen J Charron Journal: Endocrinology Date: 2017-09-01 Impact factor: 4.736
Authors: Neeraj K Sharma; Satria P Sajuthi; Jeff W Chou; Jorge Calles-Escandon; Jamehl Demons; Samantha Rogers; Lijun Ma; Nicholette D Palmer; David R McWilliams; John Beal; Mary E Comeau; Kristina Cherry; Gregory A Hawkins; Lata Menon; Ethel Kouba; Donna Davis; Marcie Burris; Sara J Byerly; Linda Easter; Donald W Bowden; Barry I Freedman; Carl D Langefeld; Swapan K Das Journal: J Clin Endocrinol Metab Date: 2016-01-20 Impact factor: 5.958
Authors: Michael Spencer; Resat Unal; Beibei Zhu; Neda Rasouli; Robert E McGehee; Charlotte A Peterson; Philip A Kern Journal: J Clin Endocrinol Metab Date: 2011-10-12 Impact factor: 5.958
Authors: Denise E Lackey; David H Burk; Mohamed R Ali; Rouzbeh Mostaedi; William H Smith; Jiyoung Park; Philipp E Scherer; Shundra A Seay; Colin S McCoin; Paolo Bonaldo; Sean H Adams Journal: Am J Physiol Endocrinol Metab Date: 2013-12-03 Impact factor: 4.310
Authors: Ricardo Ribeiro; Cátia Monteiro; Virgínia Cunha; Maria José Oliveira; Mariana Freitas; Avelino Fraga; Paulo Príncipe; Carlos Lobato; Francisco Lobo; António Morais; Vítor Silva; José Sanches-Magalhães; Jorge Oliveira; Francisco Pina; Anabela Mota-Pinto; Carlos Lopes; Rui Medeiros Journal: J Exp Clin Cancer Res Date: 2012-04-02